Network building of proteins in a biochemical pathway: A computational biology related model for target discovery and drug-design

Current Bioinformatics

Volumn 5, Issue 4, 2010, Pages 290-295

  Chakraborty, Chiranjib ^a   Refidaff, Cref ^a   Hsu, Chi Hsin ^b   Wen, Zhi Hong ^b   Lin, Chan Shing ^b  

^a VIT UNIVERSITY   (India)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Biochemical pathway; Drug design; Network building; Target discovery

Indexed keywords

BIOCHEMICAL PATHWAY; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG DESIGN STRATEGIES; DRUG TARGETS; NETWORK BUILDING; NETWORK-BASED; POTENTIAL DRUG TARGETS; TARGET CLASS; TARGET DISCOVERY;

ENZYME INHIBITION;

ALPHA SYNUCLEIN; APOLIPOPROTEIN E; CYCLIC NUCLEOTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUROTRANSMITTER RECEPTOR; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; SPLEEN EXONUCLEASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; COMPUTER PROGRAM; DRUG DESIGN; DRUG TARGETING; HUMAN; LEARNING ALGORITHM; LIPID METABOLISM; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

EID: 78951495883     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489310794072535     Document Type: Article

References (67)

1. Chakraborty C, Hsu CH, Wen ZH, Lin CS. Recent advances of fluorescent technologies for drug discovery and development. Curr Pharm Des 2009; 15(30): 3552-70.
2. Drews J. Drug discovery: a historical perspective. Science 2000; 287(5460): 1960-4.
3. Natalie M, Margino S, Erik H, Annelieke P, Geert V, Philippe V. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Toxicol In vitro 2009; 23(2): 217-26.
4. Collins LA, Torrero MN, Franzblau SG. A green fluorescent protein (GFP) microplate assay (GFPMA) for the high throughput screening of compounds against Mycobacterium tuberculosis was developed. Antimicrob Agents Chemother 1998; 42: 344-7.
5. Broder S, Venter JC. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Ann Rev Pharmacol Toxicol 2000; 40: 97-132.
6. Chanda SK, Caldwell JS. Fulfilling the promise: drug discovery in the postgenomic era. Drug Discov Today 2003; 8(4): 168-74.
7. Davidov E, Holland J, Marple E, Naylor S. Advancing drug discovery through systems biology. Drug Discov Today 2003; 8(4): 175-83.
8. Smith C. Hitting the target. Nature 2003; 422: 341-7
9. Takenaka T. Classical vs reverse pharmacology in drug discovery. BJU International 2001; 88(2): 7-10.
10. Teichmann SA, Rison SC, Thornton JM, Riley M, Gough J, Chothia C. The evolution and structural anatomy of the small molecule metabolic pathways in Escherichia coli. J Mol Biol 2001; 311: 693-708.
11. Hatzimanikatis V, Li C, Ionita JA, Broadbelt LJ. Metabolic networks: enzyme function and metabolite structure. Curr Opin Struct Biol 2004; 14: 300-6.
12. Arita M. The metabolic world of Escherichia coli is not small. Proc Natl Acad Sci 2004; 101(6): 1543-7.
13. Ma HW, Zhao XM, Yuan YJ, Zeng AP. Decomposition of metabolic network into functional modules based on the global connectivity structure of reaction graph. Bioinformatics 2004; 20(12): 1870-6.
14. Jeong H, Oltvai ZN, Barabasiv AL. Prediction of protein essentiality based on genomic data. ComPlexUs 2003; 1: 19-28.
15. Neefjes J, Dantuma NP. Fluorescent probes for proteolysis: tools for drug discovery. Nat Rev Drug Discov 2004; 3: 58-69.
16. Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov 2003; 2: 611-2.
17. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-11.
18. Bhalla US, Iyengar R. Emergent properties of networks of biological signaling pathways. Science 1999; 283(5400): 381-7.
19. Viswanathan GA, Seto J, Patil S, Nudelman G, Sealfon SC. Getting started in biological pathway construction and analysis. PLoS Comput Biol 2008; 4(2): e16.
20. Matthews LR, Vaglio P, Reboul J, et al. Identification of potential interaction networks using sequence based searches for conserved protein-protein interactions or "interologs." Genome Res 2001; 11: 2120-6.
21. Yu H, Luscombe NM, Lu HX, et al. Annotation transfer between genomes: protein-protein interologs and protein-DNA regulogs. Genome Res 2004; 14(6): 1107-18.
22. Oda K, Kitano H. A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 2006; 2: 2006.0015.
23. Kelley BP, Sharan R, Karp RM, et al. Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci USA 2003; 100: 11394-9.
24. Sharan R, Ideker T, Kelley B, Shamir R, Karp RM. Identification of protein complexes by comparative analysis of yeast and bacterial protein interaction data. J Comput Biol 2005; 12: 835-46.
25. Yeh I, Hanekamp T, Tsoka S, Karp PD, Altman RB. Computational analysis of plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res 2004; 14: 917-24.
26. Suthram S, Sittler T, Ideker T. The Plasmodium protein network diverges from those of other eukaryotes. Nature 2005; 438: 108-12
27. Cornish-Bowden A. Why is uncompetitive inhibition so rare? FEBS Lett 1986; 203(1): 3-6.
28. Cornish-Bowden A, Ofmeyr JS. The role of stoichiometric analysis in studies of metabolism: an example. J Theor Biol 2002; 216: 179-91.
29. Nikolsky Y, Nikolskaya T, Bugrim A. Biological networks and analysis of experimental data in drug discovery. Drug Discov Today 2005; 10(9): 653-62.
30. Prill RJ, Iglesias PA, Levchenko A. Dynamic properties of network motifs contribute to biological network organization. PLoS Biol 2005; 3(11): e343.
31. Barabási AL, Albert R. Emergence of scaling in random networks. Science 1999; 286: 509-12.
32. Yoon J, Blumer A, Lee K. An algorithm for modularity analysis of directed and weighted biological networks based on edge-betweenness centrality. Bioinformatics 2006; 22: 3106-8.
33. Dong J, Horvath S. Understanding network concepts in modules. BMC Syst Biol 2007; 1: 24.
34. Barabási AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004; 5: 101-13.
35. Watts DJ, Strogatz SH. Collective dynamics of 'small-world' networks. Nature 1998; 393: 440-2.
36. Diestel R. Graph theory. Heidelberg: Springer-Verlag 2005.
37. Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science 2002; 296: 910-3.
38. Papadopoulos AN, Manolopoulos Y. Nearest neighbor queries in shared-nothing environments. Geoinformatica 1997; 1: 369-92.
39. Stelzl U, Worm U, Lalowski M, et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005; 122:957-68.
40. Dandekar T, Schuster S, Snel B, Huynen M, Bork P. Pathway alignment: application to the comparative analysis of glycolytic enzymes. Biochem J 1999; 1:115-24.
41. Liao L, Kim S, Tomb JF. Genome comparisons based on profiles of metabolic pathways. In: Sixth International Conference on Knowledge-Based Intelligent Information and Engineering Systems (KES 2002). Crema, Italy 2002; pp. 469-76.
42. Sridhar P, Kahveci T, Ranka S. An iterative algorithm for metabolic network-based drug target identification. Pac Symp Biocomput 2007; pp. 88-99.
43. Bader JS, Chaudhuri A, Rothberg JM, Chant J. Gaining confidence in high-throughput protein interaction networks. Nat Biotechnol 2004; 22: 78-85.
44. Deng M, Sun F, Chen T. Assessment of the reliability of protein protein interactions and protein function prediction. Pac Symp Bio-comput 2003; 8: 140-51.
45. Zhenping L, Zhang S, Wang Y, Zhang XS, Chen L. Alignment of molecular networks by integer quadratic programming. Bioinformatics 2007; 23(13): 1631-9.
46. Stromback L, Jakoniene V, Tan H, Lambrix P. Representing, storing and accessing molecular interaction data: a review of models and tools. Brief Bioinform 2006; 7: 331-8.
47. Stromback L, Lambrix P. Representations of molecular pathways: an evaluation of SBML, PSI MI and BioPAX. Bioinformatics 2005; 21(24): 4401-7.
48. Stromback L, Jakoniene V, Tan H, Lambrix P. Representing, storing and accessing molecular interaction data: a review of models and tools. Brief Bioinform 2006; 7(4): 331-8.
49. Cary MP, Bader GD, Sander C. Pathway information for systems biology. FEBS Lett 2005; 579: 1815-20.
50. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, Bringas R. BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics 2010; 11: 91
51. Wozniak M, Tiuryn J, Dutkowski J. MODEVO: exploring modularity and evolution of protein interaction networks. Bioinformatics 2010 (Accepted).
52. Takenaka T. Classical vs reverse pharmacology in drug discovery. BJU Int 2001; 88(2): 7-10.
53. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004; 86(11): 839-48.
54. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
55. Besnard V, Wert SE, Stahlman MT, et al. Deletion of Scap in alveolar type ii cells influences lung lipid homeostasis and identifies a compensatory role for pulmonary lipofibroblasts. J Biol Chem 2009; 284(6): 4018-30.
56. Saxena U. Lipid metabolism and Alzheimer's disease: pathways and possibilities. Expert Opin Ther Targets 2009; 13: 331-8.
57. Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics, and proteomics of Alz-heimer's disease. J Clin Psychiatry 2006; 67(4): 652-70.
58. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8(7): 553-9.
59. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270.
60. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipo-protein. Eur J Lipid Res 1999; 40(1): 1-16.
61. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995; 82(2): 331-40.
62. Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004; 7(6): 575-80.
63. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395(6701): 451-2.
64. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001; 7(10): 1144-50.
65. Hall IP. Pharmacogenetics of asthma. Eur Respir J 2000; 15(3): 449-51.
66. Hall IP, Sayers I. Pharmacogenetics and asthma: false hope or new dawn? Eur Respir J 2007; 29(6): 1239-45.
67. Beavo JA, Brunton LL. Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol 2002; 3(9): 710-8.